Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Immunohistochemical status of p53 as prognostic factor in patients with node negative triple-negative breast cancer

Date

10 Oct 2016

Session

Poster display

Presenters

Soo Youn Bae

Citation

Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364

Authors

S.Y. Bae, J.E. Lee, S.K. Lee, S.J. Nam

Author affiliations

  • Department Of Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
More

Resources

Abstract 3768

Background

TP53 mutations are the most common genomic alteration in TNBC, translation of p53 into the clinical setting is particularly pertinent in TNBC, with p53 mutations reported in over 60–88% of TNBC or BLBCs, compared with only 13–26% of luminal breast cancers. However, despite the high incidence of genetic alterations in breast cancer, there is no consensus about the clinical application of p53 to management breast cancer.

Methods

We retrospectively reviewed the clinicopathologic records of patients diagnosed with surgically treated invasive breast cancer at Samsung Medical Center between Jan. 2003 and Apr. 2013. During these periods, 7739 patients with complete pathologic data, including tumor size, nuclear grade, multiple tumors, the presence of lymphovascular invasion (LVI), TNM stage, and the expression of estrogen receptor (ER), progesterone receptor (PR) and HER2, Ki-67 and p53 were included in the analysis.

Results

Median follow-up duration of patients was 57 months (4-140 months). Median age of patients was 48 years (21-78 years) Of total 1129 patients, 732 patients (64.8%) had no LN metastasis and 397 patients had LN metastasis. In TNBC patients without LN metastasis, p53+ tumors had shown higher nuclear grade than p53- tumors (87.2% vs.81.5%, P = 0.034). And, p53+ tumors had shown higher EGFR expression than p53- tumors (90.7% vs. 84.8%, P = 0.039). With multivariate analysis, p53 expression (p53+) had shown significantly better OS than patients without p53 expression (p53-) (p53+ VS. p53-; HR 2.8, 95% confidence interval: 1.1-7.1, P = 0.022) . However, in patients with LN metastasis, p53+ expression was not associated with DFS, However, in TNBC patients with LN metastasis, there was no difference of clinicopathologic characteristics between p53+ tumors and p53- tumors. And, there was no association with survival, neither DFS nor OS.

Conclusions

Conclusively, in TNBC, p53 expression was associated with better OS in patients with node-negative, not in patients with node-metastasis. These results suggest that p53 expression could be a favorable prognostic factor in early TNBC.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings